GlucoTrack Inc. (NASDAQ:GCTK) shares surged 70.25% to $0.49 after the bell on Wednesday, following the announcement that its subsidiary, Lokahi Therapeutics, is advancing a simplified single-injection strategy for its LT-100 program.
Single-Injection Strategy Fuels Rally
The LT-100 program is a clinical development project evaluating Apitox, a purified honeybee venom biologic, as a treatment for knee pain caused by osteoarthritis.
According to GlucoTrack’s after-market announcement, nonclinical minipig data support evaluating LT-100 as one subcutaneous injection per visit, replacing a historical regimen of up to 15 intradermal injections. The results follow a May 2026 Food and Drug Administration Type C meeting and are expected to inform clinical evaluation as early as the fourth quarter of 2026, with an initial readout targeted for the first half of 2027.
CEO Erik Emerson said, “The difference between 15 injections and one injection speaks for itself.”
Debt Restructuring
On Monday, the New Jersey-based medical technology company disclosed in a Securities and Exchange Commission filing that it had entered into an Exchange Agreement partitioning a $900,000 “Partitioned Note” from an existing $3.6 million promissory note originally issued in September 2025. Under the deal, the investor can convert the note into common shares priced at the lower of Nasdaq’s latest closing price or a five-day average, capped at 9.99% beneficial ownership.
Trading Metrics, Technical Analysis
GlucoTrack has a market capitalization of $2.20 million, with a 52-week high of $14.14 and a 52-week low of $0.25.
The Relative Strength Index (RSI) of GCTK stands at 34.54.
The stock experienced an exceptionally elevated trading session. Volume reached 24.19 million shares, more than 4.05 times the stock’s average daily volume of 5.97 million shares.
Over the past 12 months, the stock has declined 95.51%.
It is currently trading near its 52-week low.
GCTK’s sharp decline and weak market position suggest that the stock may continue to face pressure, highlighting increased risk and the need for clearer signs of recovery before investor confidence can return.
Price Action: The stock closed at $0.28 on Wednesday, down 5%, according to Benzinga Pro data.
Benzinga’s Edge Stock Rankings indicate that GCTK has a negative price trend across all time frames.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo: Ole.CNX / Shutterstock
Login to comment